- Home
- Companies
- Genmab A/S
- Products
- Genmab Amivantamab - Human Bispecific ...
Genmab Amivantamab - Human Bispecific Antibody
Amivantamab is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform. The two antibody libraries used to produce amivantamab were both generated by Genmab. The antibody pair used to create Amivantamab was selected in collaboration between Genmab and Janssen. Subsequent development work was carried out by Janssen.
In 2021, Janssen received approval from the U.S. FDA for amivantamab-vmjw (RYBREVANT®) for the treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
This is the first regulatory approval for a therapy that was created using Genmab’s proprietary DuoBody® bispecific technology platform.
Indication and Safety
For more information related to the U.S. FDA approval, including indication,